Axsome Therapeutics Inc AXSM

NAS: AXSM | ISIN: US05464T1043   30/04/2025
112,29 USD (+2,16%)
(+2,16%)   30/04/2025

22 februari 2023 · Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe · Persbericht

13 augustus 2022 · AXSOME THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Axsome Therapeutics, Inc. - AXSM · Persbericht

23 juni 2022 · AXSM Investors Have Opportunity to Lead Axsome Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

31 mei 2022 · Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry · Persbericht

18 mei 2022 · Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry · Persbericht

16 mei 2022 · Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month · Persbericht

9 mei 2022 · Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea · Persbericht

9 mei 2022 · Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics · Persbericht

2 mei 2022 · Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update · Persbericht

2 mei 2022 · Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine · Persbericht

25 april 2022 · Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022 · Persbericht

19 februari 2021 · Axsome Therapeutics to Present at Upcoming Investor Conferences · Persbericht

Mijn selecties